Menu
Back to Journals » Breast Cancer: Targets and Therapy » Volume 14 » default
Breast Cancer: Targets and Therapy
ISSN: 1179-1314
- View all (488)
- Volume 16, 2024 (17)
- Volume 15, 2023 (79)
- Volume 14, 2022 (41)
- Volume 13, 2021 (58)
- Volume 12, 2020 (27)
- Volume 11, 2019 (32)
- Volume 10, 2018 (24)
- Volume 9, 2017 (64)
- Volume 8, 2016 (26)
- Volume 7, 2015 (36)
- Volume 6, 2014 (20)
- Volume 5, 2013 (13)
- Volume 4, 2012 (22)
- Volume 3, 2011 (16)
- Volume 2, 2010 (9)
- Volume 1, 2009 (4)
Archive: Volume 14, 2022
Chromobox Family Proteins as Putative Biomarkers for Breast Cancer Management: A Preliminary Study Based on Bioinformatics Analysis and qRT-PCR Validation
Tian H, Zhao T, Li Y, Sun N, Ma D, Shi Q, Zhang G, Chen Q, Zhang K, Chen C, Zhang Y, Qi X
Breast Cancer: Targets and Therapy 2022, 14:515-535
Published Date: 30 December 2022
Whole Genome Sequencing of Single-Circulating Tumor Cell Ameliorates Unraveling Breast Cancer Heterogeneity
Li Y, Jiang X, Zhong M, Yu B, Yuan H
Breast Cancer: Targets and Therapy 2022, 14:505-513
Published Date: 28 December 2022
Real-World Outcome and Prognostic Factors Among HER2-Positive Metastatic Breast Cancer Patients Receiving Pyrotinib-Based Therapy: A Multicenter Retrospective Analysis
Liu J, Sun X, Du Q, Yao J, Dai M, Cheng Q, Xu H, Li Y, Liu X, Zhang M, Zhou Y, Yang Y
Breast Cancer: Targets and Therapy 2022, 14:491-504
Published Date: 21 December 2022
Factors Predicting Positive Sentinel Lymph Node Biopsy in Clinically Node-Negative Breast Cancer [Letter]
Zhang JY, Xu BH
Breast Cancer: Targets and Therapy 2022, 14:489-490
Published Date: 21 December 2022
Predictive and Prognostic Value of TRIM58 Protein Expression in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy
Zheng YZ, Li JY, Ning LW, Xie N
Breast Cancer: Targets and Therapy 2022, 14:475-487
Published Date: 21 December 2022
Advances in Single-Cell Sequencing Technology and Its Applications in Triple-Negative Breast Cancer
Li M, Yan T, Wang M, Cai Y, Wei Y
Breast Cancer: Targets and Therapy 2022, 14:465-474
Published Date: 14 December 2022
Economic Evaluation of Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer in the United States
Lang Y, Wu B, Liu X
Breast Cancer: Targets and Therapy 2022, 14:453-463
Published Date: 9 December 2022
Effect of Chemotherapy on the Gut Microbiome of Breast Cancer Patients During the First Year of Treatment
Wu AH, Vigen C, Tseng C, Garcia AA, Spicer D
Breast Cancer: Targets and Therapy 2022, 14:433-451
Published Date: 9 December 2022
Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer
Yu Y, Wang J, Liao D, Zhang D, Li X, Jia Y, Kong F
Breast Cancer: Targets and Therapy 2022, 14:417-432
Published Date: 9 December 2022
Pyrotinib for Elderly Patients with Advanced HER2-Positive Breast Cancer
Li Y, Ma X, Zhao Z, Li L, Gao C, Liu D, Li B, Zhao B
Breast Cancer: Targets and Therapy 2022, 14:405-415
Published Date: 6 December 2022
Metformin Inducing the Change of Functional and Exhausted Phenotypic Tumor-Infiltrated Lymphocytes and the Correlation with JNK Signal Pathway in Triple-Negative Breast Cancer
Wang R, Li Y, Zhao Y, Shi F, Zhou Q, Wu J, Lyu S, Song Q
Breast Cancer: Targets and Therapy 2022, 14:391-403
Published Date: 2 December 2022
Establishment and Validation of a Model for Disease-Free Survival Rate Prediction Using the Combination of microRNA-381 and Clinical Indicators in Patients with Breast Cancer
Shen J, Wang M, Li F, Yan H, Wang R, Zhou J
Breast Cancer: Targets and Therapy 2022, 14:375-389
Published Date: 30 November 2022
Clinical Characteristics and Survival Outcomes of Patients with De Novo Metastatic Breast Cancer
Almasri H, Erjan A, Abudawaba H, Ashouri K, Mheid S, Alnsour A, Abdel-Razeq H
Breast Cancer: Targets and Therapy 2022, 14:363-373
Published Date: 29 October 2022
Ribociclib Plus Letrozole in Italian Male Patients with Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Case Studies of Phase 3b CompLEEment-1 Trial
Caputo R, Fabi A, Romagnoli E, Baldini E, Grasso D, Fenderico N, Michelotti A
Breast Cancer: Targets and Therapy 2022, 14:351-362
Published Date: 18 October 2022
Evaluating the Fragility of Long-Term Outcomes for Neoadjuvant versus Adjuvant Chemotherapy Prescription in Early Breast Cancer: Pooled Data from 10 Randomised Clinical Trials
Davey MG, Kerin MJ
Breast Cancer: Targets and Therapy 2022, 14:343-350
Published Date: 17 October 2022
Development and Validation of an MRI Radiomics-Based Signature to Predict Histological Grade in Patients with Invasive Breast Cancer
Wang S, Wei Y, Li Z, Xu J, Zhou Y
Breast Cancer: Targets and Therapy 2022, 14:335-342
Published Date: 14 October 2022
Factors Predicting Positive Sentinel Lymph Node Biopsy in Clinically Node-Negative Breast Cancer
Alsumai TS, Alhazzaa N, Alshamrani A, Assiri S, Alhefdhi A
Breast Cancer: Targets and Therapy 2022, 14:323-334
Published Date: 11 October 2022
The Involvement of Insulin-Like Growth Factor 2 Messenger Ribonucleic Acid-Binding Protein 2 in the Regulation of the Expression of Breast Cancer-Related Genes
Gao C, Li L, Jin X, Song X, Li H, Xu X, Dong C, Ma B
Breast Cancer: Targets and Therapy 2022, 14:311-322
Published Date: 10 October 2022
The Notch Signaling Pathway Contributes to Angiogenesis and Tumor Immunity in Breast Cancer
Jiang N, Hu Y, Wang M, Zhao Z, Li M
Breast Cancer: Targets and Therapy 2022, 14:291-309
Published Date: 27 September 2022
Is Routine Intraoperative Frozen Section Analysis of Sentinel Lymph Nodes Necessary in Every Early-Stage Breast Cancer?
Lerttiendamrong B, Treeratanapun N, Vacharathit V, Tantiphlachiva K, Vongwattanakit P, Manasnayakorn S, Vongsaisuwon M
Breast Cancer: Targets and Therapy 2022, 14:281-290
Published Date: 19 September 2022
Breast Cancer Subtypes and Prognosis: Answers to Subgroup Classification Questions, Identifying the Worst Subgroup in Our Single-Center Series
Cosar R, Sut N, Ozen A, Tastekin E, Topaloglu S, Cicin I, Nurlu D, Ozler T, Demir S, Yıldız G, Şenödeyici E, Uzal MC
Breast Cancer: Targets and Therapy 2022, 14:259-280
Published Date: 8 September 2022
Chloride Intracellular Channel 1 is a Potential Biomarker for Breast Cancer
Xia J, Wang Q, Ju F, Luo X, Wang F, Zhou Y, Huang H, Wang H, Bao X
Breast Cancer: Targets and Therapy 2022, 14:247-258
Published Date: 2 September 2022
A Scoping Review on the Status of Female Breast Cancer in Asia with a Special Focus on Nepal
Dhakal R, Noula M, Roupa Z, Yamasaki EN
Breast Cancer: Targets and Therapy 2022, 14:229-246
Published Date: 26 August 2022
Ovo Like Zinc Finger 2 (OVOL2) Suppresses Breast Cancer Stem Cell Traits and Correlates with Immune Cells Infiltration
Wu J, Luo D, Li S
Breast Cancer: Targets and Therapy 2022, 14:211-227
Published Date: 15 August 2022
A Real-World Data Retrospective Cohort Study of Low Estrogen Receptor-Positive Early Breast Cancer: Natural History and Treatment Outcomes
Bari S, Boulware D, Li J, Loftus L, Soyano Muller A, Jameel Z, Khong H, Czerniecki BJ, Costa RLB
Breast Cancer: Targets and Therapy 2022, 14:199-210
Published Date: 6 August 2022
miR-623 Targets Metalloproteinase-1 and Attenuates Extravasation of Brain Metastatic Triple-Negative Breast Cancer Cells
Hammash D, Mahfood M, Khoder G, Ahmed M, Tlili A, Hamoudi R, Harati R
Breast Cancer: Targets and Therapy 2022, 14:187-198
Published Date: 1 August 2022
Heart Sparing Radiotherapy Techniques in Breast Cancer: A Focus on Deep Inspiration Breath Hold
Stowe HB, Andruska ND, Reynoso F, Thomas M, Bergom C
Breast Cancer: Targets and Therapy 2022, 14:175-186
Published Date: 20 July 2022
Cancer Treatment-Induced Bone Loss: Role of Denosumab in Non-Metastatic Breast Cancer
Dhabhar B
Breast Cancer: Targets and Therapy 2022, 14:163-173
Published Date: 14 July 2022
The Effect of Estrogen Receptor Status on Survival in Breast Cancer Patients in Ethiopia. Retrospective Cohort Study
Belete AM, Aynalem YA, Gemeda BN, Demelew TM, Shiferaw WS
Breast Cancer: Targets and Therapy 2022, 14:153-161
Published Date: 17 June 2022
Occult Invasive Lobular Carcinoma Presenting as an Axillary Skin Metastatic Lesion Underwent Neoadjuvant Endocrine Therapy and Surgical Resection: A Case Report and Review of Literature
Busbait S, Alkhalifa AM, Aljohani S, Alhaddad H
Breast Cancer: Targets and Therapy 2022, 14:145-152
Published Date: 31 May 2022
The Predictive Effect of the 8th AJCC Pathological Prognostic Staging on the Benefit of Postmastectomy Radiotherapy in N2/N3 Breast Cancer
Yang SP, Zhou P, Lian CL, He ZY, Wu SG
Breast Cancer: Targets and Therapy 2022, 14:133-144
Published Date: 13 May 2022
Breast Cancer in Italy: Stage and Region Distribution
Mangone L, Bisceglia I, Michiara M, Musolino A, Mazzoleni G, Caldarella A, Minerba S, Cascone G, Bella F, Dinaro Y, Pau L, Pinto C
Breast Cancer: Targets and Therapy 2022, 14:125-131
Published Date: 29 April 2022
Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab
Bagegni NA, Davis AA, Clifton KK, Ademuyiwa FO
Breast Cancer: Targets and Therapy 2022, 14:113-123
Published Date: 29 April 2022
Ribociclib in the Treatment of Hormone-Receptor Positive/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection
Parati MC, Pedersini R, Perego G, Reduzzi R, Savio T, Cabiddu M, Borgonovo K, Ghilardi M, Luciani A, Petrelli F
Breast Cancer: Targets and Therapy 2022, 14:101-111
Published Date: 12 April 2022
Cross-Platform in-silico Analyses Exploring Tumor Immune Microenvironment with Prognostic Value in Triple-Negative Breast Cancer
Kok VC, Wang CCN, Liao SH, Chen DL
Breast Cancer: Targets and Therapy 2022, 14:85-99
Published Date: 12 April 2022
Polyethyleneimine (PEI) as a Polymer-Based Co-Delivery System for Breast Cancer Therapy
Fahira AI, Amalia R, Barliana MI, Gatera VA, Abdulah R
Breast Cancer: Targets and Therapy 2022, 14:71-83
Published Date: 8 April 2022
Weekly vs Every-3-Week Carboplatin with Weekly Paclitaxel in Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Retrospective Analysis
Landry KK, Lyon JL, Victoria KE, Changizzadeh PN, Cole BF, Pulluri B, Sikov WM, Wood ME
Breast Cancer: Targets and Therapy 2022, 14:63-70
Published Date: 15 March 2022
Micropapillary Breast Carcinoma: From Molecular Pathogenesis to Prognosis
Verras GI, Tchabashvili L, Mulita F, Grypari IM, Sourouni S, Panagodimou E, Argentou MI
Breast Cancer: Targets and Therapy 2022, 14:41-61
Published Date: 12 March 2022
miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy
Normann LS, Haugen MH, Aure MR, Kristensen VN, Mælandsmo GM, Sahlberg KK
Breast Cancer: Targets and Therapy 2022, 14:25-39
Published Date: 1 March 2022
Treatment Strategies Against Triple-Negative Breast Cancer: An Updated Review
Maqbool M, Bekele F, Fekadu G
Breast Cancer: Targets and Therapy 2022, 14:15-24
Published Date: 11 January 2022
Central Nervous System Metastases from Triple-Negative Breast Cancer: Current Treatments and Future Prospective
Kadamkulam Syriac A, Nandu NS, Leone JP
Breast Cancer: Targets and Therapy 2022, 14:1-13
Published Date: 10 January 2022